Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted strong financial performance with a 5% revenue increase, improved gross margin, and a 15% EPS rise, indicating operational efficiency and cost management. Despite acknowledging risks in forward-looking statements, the overall financial health and growth prospects, including increased free cash flow, suggest a positive market reaction.
Key Financial Performance
Revenue Revenue for Q1 2026 was $1.2 billion, representing a 5% increase year-over-year. This growth was driven by strong performance in the companion animal segment and increased demand for innovative products.
Gross Margin Gross margin improved to 55%, up from 53% in Q1 2025, reflecting operational efficiencies and favorable product mix.
Operating Expenses Operating expenses were $450 million, a 2% increase year-over-year, primarily due to investments in R&D and marketing initiatives.
Net Income Net income was $150 million, up 10% compared to Q1 2025, driven by higher revenue and improved cost management.
Earnings Per Share (EPS) Earnings per share for Q1 2026 were $0.30, a 15% increase year-over-year, supported by revenue growth and margin expansion.
Free Cash Flow Free cash flow was $200 million, a 20% increase from Q1 2025, attributed to improved working capital management and higher profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that its forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from forecasts.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Animal Health
Blair LLC
BofA Securities
CEO Director
CFO Jonathan
Citigroup Inc
Clark Leerink
Dechert KeyBanc
Dietschi BNP
Director VanHimbergen
Division Brandon
Division Clark
Division Dechert
Division EDT
Division Grosslight
Division Navann
Division Ryskin
Division Schott
Division Umer
EDT day
ESG President
ESG Today
Elanco Animal
Executive VP
Inc Research
Incorporated
Investor Relations
LLC Research
Relations ESG
risk
ELAN Transcript
Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call highlighted strong financial performance with a 5% revenue increase, improved gross margin, and a 15% EPS rise, indicating operational efficiency and cost management. Despite acknowledging risks in forward-looking statements, the overall financial health and growth prospects, including increased free cash flow, suggest a positive market reaction.
Elanco Animal Health Incorporated (ELAN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-11
Elanco Animal Health Incorporated (ELAN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Elanco Animal Health Incorporated (ELAN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
ELAN Slides
Elanco Q4 2025 slides: innovation drives growth, debt falls faster2026-02-24
Elanco Q3 2025 slides: Innovation drives 9% revenue growth, guidance raised2025-11-05
Elanco Q2 2025 slides: 8% organic growth drives raised guidance despite headwinds2025-08-07
Elanco Q1 2025 slides: Revenue guidance raised amid innovation-driven growth2025-05-07
ELAN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
